Navigation Links
CardioVascular BioTherapeutics Submits FDA Application for 'Fast Track' Status for CVBT-141B, CVBT's Biological Treatment for Diabetes Patients

LAS VEGAS, Feb. 3, 2011 /PRNewswire/ -- CardioVascular BioTherapeutics, Inc. (Pink Sheets: CVBT) today announced it has submitted an application to the U.S. FDA to obtain "fast track" designation for CVBT-141B, its biological therapy to treat ischemic diabetic wounds based on the active ingredient fibroblast growth factor-1 (FGF-1).  The FDA grants "fast track" designation to accelerate the development of promising new therapies that treat a serious medical condition and for which there are no available therapies that adequately address the problem.

CVBT believes CVBT-141B meets the FDA's criteria, as ischemic diabetic wounds, if not successfully treated, can lead to infection, sepsis, amputation, and death.  Even with currently-available treatments, there are more than 80,000 foot amputations per year in the diabetic patient population.  CVBT-141B is targeted at reducing the suffering in the diabetes community by closing ischemic diabetic wounds much more rapidly, thereby halting the all-too-common progression to infection, gangrene, amputation, and death.

CVBT's CEO, Daniel C. Montano, stated, "This is a major development for CVBT's ischemic diabetic wound healing program as well as for diabetes patients.  The Centers for Disease Control and Prevention (CDC) reports that approximately 26 million Americans suffer from diabetes, while published peer-reviewed statistics indicate that 15% to 25% of these patients (3.9 million to 6.5 million patients) will eventually develop a diabetic foot wound at some point in their lifetime(i). Further, additional published peer-reviewed statistics indicate that in any given year, between 2% and 5% of diabetes patients (520,000 to 1.3 million patients annually) will develop one of these wounds(ii). Ischemic diabetic wounds are the most difficult of to heal. This is a life-threatening health problem for which there is urgent need for more effective treatments."

On January 4, 2011, CVBT released summarized results of the Phase II trials.  In the Phase IIa trial, diabetic wounds treated with FGF-1 healed approximately 4.5 times faster than wounds treated with placebo/standard of care (which included debridement). In the Phase IIb trial, all of the diabetic wounds treated with FGF-1 achieved 100% closure within five months or less, whereas a full one-third of the placebo-treated wounds remained open at the end of the same treatment period.  Additionally, 57% of patients treated with FGF-1 had complete closure of their diabetic wounds at eight weeks, versus 0% for the placebo group.  Both Phase II trials demonstrated statistical significance to placebo (p<0.05).  In all trials (Phase I and Phase II), there have been no significant safety or adverse events attributable to the drug.

Subject to FDA approval, CVBT anticipates commencement of the Phase III trial for CVBT-141B in 2011.

About CardioVascular BioTherapeuticsCVBT is a biopharmaceutical company developing drug candidates with FGF-1 as its active pharmaceutical ingredient (API) for diseases characterized by inadequate blood flow to tissue or organs. The company has a Phase II trial to treat severe coronary heart disease (CVBT-141H) underway, and has received FDA authorization for a Phase I trial to treat peripheral arterial disease (CVBT-141C). A Phase III trial to treat diabetic wounds (CVBT-141B) is planned pending FDA approval.

This news release contains forward-looking statements that involve risks and uncertainties. Actual results and outcomes may differ materially from those discussed or anticipated. For example, statements regarding expectations for new research, progress with clinical trials or future business initiatives are forward looking statements. Factors that might affect actual outcomes include, but are not limited to, FDA approval of CVBT drug candidates, market acceptance of CVBT products by customers, new developments in the industry, future revenues, future expenses, future margins, cash usage and financial performance. For a more detailed discussion of these and associated risks, see the company's most recent documents filed with the Securities and Exchange Commission.References:(i) Robert J. Snyder and Jason R. Hanft, Ostomy Wound Management, 2009, Vol. 55, #11, pp. 28-38.(ii) Boyko, 2006; Abbott, 2002; Ramsey, 1999 (see attached)Media Contact:Allison CaplanCardioVascular BioTherapeutics, Inc.(702)

SOURCE CardioVascular BioTherapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pervasis to Present Interim Data from Phase 1/2 Clinical Study of Novel Cell Therapy Targeting Peripheral Artery Disease at International Conference on Cell Therapy for Cardiovascular Diseases
2. Reportlinker Adds Europe Cardiovascular Devices Market Outlook to 2016
3. Prescient Medical, Inc. Presenting at the 5th Annual Canaccord Genuity Cardiovascular Conference
4. Amarin to Present at Canaccord Genuity Cardiovascular, Diabetes & Obesity Conference
5. InfraReDx to Present at Canaccord Genuity 5th Annual Cardiovascular, Diabetes & Obesity Conference
6. BMEYE Receives FDA Clearance to Launch ccNexfin, the First Totally Noninvasive Cardiovascular Monitor With BP, CO, and Masimo Rainbow SET(R) Technology in the United States
7. Study Highlights Incidence of Cardiovascular Disease-Related Events and All-Cause Hospitalizations Associated with BYETTA® Compared to Insulin, Thiazolidinediones, Sulfonylureas, Metformin and Januvia®
8. NT-proBNP Guided Therapy Keeps Heart Failure Patients out of the Hospital Through a Reduction in Cardiovascular Events
9. Reportlinker Adds Cardiovascular Surgical Devices: The Global Market
10. Beaumont Hospital Opens New Ernst Cardiovascular Center
11. Stereotaxis Launches the Odyssey Interventional Network for Superior Online Cardiovascular Education and Training
Post Your Comments:
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... to 2022" report to their offering. ... financial data derived from varied research sources to present unique ... on the market during the next five years, including a ... markets, regional and country level analysis. The report provides a ...
(Date:6/23/2016)... 23, 2016 , , , ... 7, 2016 , , , , LOCATION: , , , ... , , , EXPERT PANELISTS:  , , , Frost & Sullivan,s ... Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program ... global pharmaceutical industry is witnessing an exceptional era. Several new demand ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/24/2016)... ... 24, 2016 , ... Those who have experienced traumatic events may suffer from ... avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid this ... coping following a traumatic event. , Trauma sufferers tend to feel a range of ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, ... Elite. The attorneys chosen by their peers for this recognition are considered among the ... Traurig Shareholders received special honors as members of this year’s Legal Elite Hall of ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. ... magazine’s Code Talker Award, an essay contest in which patients and their families pay ... be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... is actively feeding the Frederick area economy by obtaining investment capital for emerging ... the past 2½ years that have already resulted in more than a million ...
Breaking Medicine News(10 mins):